Proteolysis targeting chimeras (PROTACs) technology is a novel and promising therapeutic
strategy using small molecules to induce ubiquitin-dependent degradation of proteins. It has …

Polycomb group (PcG) proteins are crucial chromatin regulators that maintain repression of
lineage-inappropriate genes and are therefore required for stable cell fate. Recent advances …

Enhancer elements in the human genome control how genes are expressed in specific cell
types and harbor thousands of genetic variants that influence risk for common diseases …

Cancers adapt to increasingly potent targeted therapies by reprogramming their phenotype.
Here we investigated such a phenomenon in prostate cancer, in which tumours can escape …

The Polycomb group (PcG) of proteins defines a subset of factors that physically associate
and function to maintain the positional identity of cells from the embryo to adult stages. PcG …

Deregulation of the PRC2 complex, comprised of the core subunits EZH2, SUZ12, and EED,
drives aberrant hypermethylation of H3K27 and tumorigenicity of many cancers. Although …

Polycomb group proteins are transcriptional repressors that are essential for normal gene
regulation during development. Recent studies suggest that Polycomb repressive …

The GATA family of transcription factors is of crucial importance during embryonic
development, playing complex and widespread roles in cell fate decisions and tissue …

EZH2 mediates both PRC2-dependent gene silencing via catalyzing H3K27me3 and PRC2-
independent transcriptional activation in various cancers. Given its oncogenic role in …

Enhancers are the primary determinants of cell identity, but the regulatory components
controlling enhancer turnover during lineage commitment remain largely unknown. Here we …